Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
Date:3/24/2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Tuesday, March 24, 2009.

At the meeting, shareholders approved the proposal to increase the number of shares of authorized stock (including an increase in the number of shares of authorized common stock), the proposal to increase the number of shares available for issuance under its 2007 Equity Incentive Plan and the proposal to increase the number of shares available for issuance under its 2007 Employee Purchase Plan. The proposal to allow the Board of Directors to implement a reverse split if and when the Board deems such action appropriate was not approved by the shareholders.

"We appreciate the support of our shareholders as it is important both from an operational and a strategic perspective as we move our products and programs toward approval," said James A. Bianco, M.D., CEO of CTI. "With excellent phase III data for pixantrone for aggressive relapsed non-Hodgkin's lymphoma we plan to complete the New Drug Application (NDA) submission in the second quarter of 2009 and we believe that this product would truly make a significant impact on this difficult to treat patient population. While we now have approval for additional authorized shares, we intend to continue to pursue product partnerships to generate operating capital."

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, our ability to submit an NDA in the first half of 2009 f
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces ... Puma Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ... filed in United States District Court, Central District of ... is on behalf of a class consisting of all ... 23, 2014 and May 13, 2015 inclusive (the "Class ...
(Date:7/2/2015)... -- Amici Procurement Migrates to the Cloud ... has chosen Microsoft Cloud Solution Provider iomart ...      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... the bio-tech sector with a unique procurement service, helping ... help them obtain best value. Its IT platform hosts ...
(Date:7/1/2015)... BURLINGTON, Mass. , July 1, 2015 /PRNewswire/ ... three most frequently cited advantages of Otezla are ... favorable safety profile, as reported by surveyed rheumatologists. ... and launched for the treatment of active psoriatic ... . The current standard of care includes conventional ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Biotech Procurement Company Moves to Office 365 with iomart 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... ... Monitoring MUKILTEO, Wash. and ALISO VIEJO, Calif., ... Clarient, Inc. (Nasdaq: CLRT ),today jointly announced establishment of ... test called HemeScan(TM), a,comprehensive test related to the treatment and ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... to full enrolment in its U.S. Phase II ... patients with,various sarcomas that have metastasized to the ... proceed to full enrolment of 52,patients, Oncolytics had ...
... as the "holy grail" of nanoscience, researchers at the ... the first time used DNA to guide the creation ... dimensions measured in billionths of a meter). The ability ... functional materials that take advantage of the unique properties ...
Cached Biology Technology:CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 2CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 3CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 4CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 5CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL) 6Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 2Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 3DNA technique yields 3-D crystalline organization of nanoparticles 2DNA technique yields 3-D crystalline organization of nanoparticles 3
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... GERMANTOWN, Maryland , and HILDEN, Germany ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today launched ... DNA evidence in forensic laboratories in the United ... integrated solution to simultaneously analyze multiple key genomic markers (short ... Investigator ® Quality Sensor to evaluate the quality of ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... has been given a welcome boost by scientists from Queen,s ... 300 of the mussels, which are threatened in many parts ... the wild at a range of secret locations in Northern ... from Queen,s will be able to keep tabs on the ...
... Society of America (GSA) biennial meeting, "GENETICS 2010: ... at the Sheraton Boston, Massachusetts, will bring together ... flies, yeast, fungi, mice and other non-human organisms, with ... of basic research on the study of human diseases ...
... "Educationally relevant health disparities" are key drivers of ... Charles Basch, the Richard March Hoe Professor of Health ... past several decades, a variety of strategies have been ... accountability, NCLB, more rigorous teacher certification and they,re ...
Cached Biology News:Queen's scientists boost endangered freshwater mussels population 2GENETICS 2010: Model Organisms to Human Biology Meeting 2GENETICS 2010: Model Organisms to Human Biology Meeting 3GENETICS 2010: Model Organisms to Human Biology Meeting 4To close achievement gap, US must address major health risks for urban minority youth, study finds 2To close achievement gap, US must address major health risks for urban minority youth, study finds 3
I-Ab MHC Class II...
... BD BioCoat Collagen I 60 mm Culture Dishes ... Dishes, tissue-culture treated polystyrene with a uniform application ... Coating : Collagen I ,Surface : ... 21.3 cm2 ,Dim nominal : 60 ...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
Biology Products: